Oklahoma Medical Research Foundation is a 501(c)(3) organization based in Oklahoma City, Oklahoma, registered in 1999, with $132,332,301 in FY2023 revenue. CharityIndex grades it A+, and it directs about 93% of spending to programs.
Revenue (FY2023)
$132.3M
▲ 15.8% vs prior year
Medical Research median: $217K
Expenses (FY2023)
$119.7M
Net assets
$489.5M
Employees
643
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Oklahoma Medical Research Foundation: 93% to programs · $4 to raise $100 earns a A+ on this criterion. See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Oklahoma Medical Research Foundation: 49 mo reserves · +10% margin earns a A on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Oklahoma Medical Research Foundation: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Oklahoma Medical Research Foundation: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Oklahoma medical research foundation (omrf) is dedicated to developing a better understanding of and more effective treatments for human disease.
Cardiovascular biology research program - early-career scientists led a watershed year for the study of diseases of the heart, blood and circulatory system. together, graduate students and postdoctoral fellows in this program earned 11 research grants and fellowships, which could blaze new treatment paths for illnesses ranging from heart attack and stroke to diabetes-related vision loss. meanwhile, the program's leader, dr. lijun xia, led research that could one day lead to a new drug to treat the pain crises in sickle cell disease. finally, an experimental therapy born from discoveries in this program began clinical trials in patients with hemophilia, the inherited blood disorder that can be life-threatening.
Aging and metabolism research program - drs. michael beckstead and harris blankenship made a groundbreaking discovery that could one day transform the lives of alzheimer's patients. in experiments with mice genetically engineered to develop a condition that mimics alzheimer's disease, they found that dopamine - a brain chemical associated with behavioral rewards - could play a crucial role in causing the deadly, memory-robbing disease. the scientists published their findings in 2024 in the influential scientific journal nature communications. "we've at least cracked the surface of something that might slow down this terrible disease," said beckstead. "with more work, we hope we can make a big difference."
Other program services include departments such as cell cycle and cancer biology, genes and human disease, center for biomedical data sciences and other scientific and research support services.
Revenue grew from $69.5M (FY2013) to $132.3M (FY2023) across 11 reported years.
Financial snapshot
Operating margin
9.5%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$528.8M
Total liabilities
$39.3M
Net assets
$489.5M
Salaries & benefits
$51.9M
43% of expenses
Board members
64
64 independent
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2023 | $132,332,301▲15.8% | $119,704,487▲10.7% | $489,469,727▲8.5% | $528,771,950▲8.8% | 990 |
| 2022 | $114,311,660▲6.1% | $108,085,497▲11.5% | $451,038,170▲4.8% | $485,930,868▲4.8% | 990 |
| 2021 | $107,744,875▼14.5% | $96,940,173▲5.0% | $430,228,505▼6.9% | $463,812,009▼7.2% | 990 |
| 2020 | $126,016,814▲32.5% | $92,338,587▲4.2% | $462,138,183▲26.8% | $499,810,540▲20.1% | 990 |
| 2019 | $95,128,697▼1.4% | $88,608,525▼1.0% | $364,359,243▲1.4% | $416,096,679▲0.2% | 990 |
| 2018 | $96,525,070▲5.2% | $89,532,385▲0.4% | $359,460,397▲2.9% | $415,080,137▲2.6% | 990 |
| 2017 | $91,783,174▲16.5% | $89,209,656▲18.8% | $349,164,541▲4.3% | $404,739,259▲3.7% | 990 |
| 2016 | $78,795,191▲8.9% | $75,113,337▲2.7% | $334,610,185▲5.8% | $390,204,230▲2.9% | 990 |
| 2015 | $72,372,648▲9.6% | $73,143,223▲1.0% | $316,304,572▼4.6% | $379,327,594▼3.4% | 990 |
| 2014 | $66,056,776▼4.9% | $72,447,910▲1.2% | $331,695,219▼2.4% | $392,496,683▼2.3% | 990 |
| 2013 | $69,467,909 | $71,560,698▲6.0% | $339,935,418▲7.0% | $401,849,018▲5.9% | 990 |
| 2012 | — | $67,482,216▼1.9% | $317,560,957▲3.0% | $379,496,939▲2.1% | 990 |
| 2011 | — | $68,760,495▲2.7% | $308,277,255▼4.1% | $371,571,744▼4.3% | 990 |
| 2010 | — | $66,920,939▲9.4% | $321,505,278▲12.6% | $388,445,536▲6.2% | 990 |
| 2009 | — | $61,149,410 | $285,621,817 | $365,771,140 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Highest-paid: Andrew Weyrich Phd — $782,054 (0.65% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Andrew Weyrich Phd | President and Ceo | 50 | $782,054 |
| Penny Voss | Vp of Philanthropy and Community Relations | 50 | $607,800 |
| Judith James | Evp and Chief Medical Officer | 50 | $523,931 |
| Gabriel Pardo Md | Professor Clinical Neurology, Arthritis and Clinical Immunology | 50 | $417,669 |
| Florea Lupu Phd | Professor, Cardiovascular Biology | 50 | $357,661 |
| Adam Cohen | Svp and General Counsel | 50 | $339,134 |
| Lijun Xia Md | Program Chair, Cardiovascular Biology | 50 | $338,683 |
| Swapan Nath Phd | Professor, Arthritis and Clinical Immunology | 50 | $329,298 |
| Patrick Gaffney Md | Program Chair, Genes and Human Disease | 50 | $321,243 |
| Courtney Griffin Phd | Vp of Research | 50 | $309,221 |
| Tim Hassen | Vp and Chief Financial Officer | 50 | $304,661 |
| Chelsea Berkley Md | Clinical Assistant Professor, Arthritis and Clinical Immunology | 50 | $265,927 |
| Joan Merrill Md | Professor, Arthritis and Clinical Immunology | 50 | $259,621 |
| Matlock Jeffries Md | Associate Professor, Arthritis and Clinical Immunology | 50 | $254,748 |
| Courtney Greenwood | Vp of Human Resources | 50 | $216,882 |
| Lisa Day | Vp of Government Relations and Advocacy | 50 | $207,669 |
| Benjamin Miller Phd | Program Chair, Aging and Metabolism | 50 | $196,258 |
| Ann Felton | Board Member | 1 | — |
| Barbara Braught | Board Member | 1 | — |
| Barry Pollard Md | Board Member | 1 | — |
| Contractor | Services | Paid |
|---|---|---|
| Infusion Management LLC | Infusion Management Services | $23,459,257 |
| Aramark | Housekeeping Services | $651,320 |
| Grant Thornton LLP | Audit Services | $126,500 |
| Captrust Partners LLC | Investment Management Services | $112,300 |
116 grants to Oklahoma Medical Research Foundation totaling $78.9M, reported by foundations on their Schedule I filings — showing the 15 most recent.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| J A & Leta M Chapman Charitable Tr | Medical research | 2024 | $10,652,892 |
| American Heart Association Inc | Research | 2024 | $1,011,816 |
| Raymond James Charitable Endowment Fund | General support | 2024 | $20,750 |
| The Dallas Foundation | General support | 2024 | $20,564 |
| Ssm Health Care of Oklahoma Inc | Charitable support | 2024 | $7,500 |
| Morgan Stanley Global Impact Funding Trust Inc | Unrestricted general support | 2024 | $5,000 |
| J A & Leta M Chapman Charitable Tr | Medical research | 2023 | $10,664,128 |
| Emory University | Research/subcontract | 2023 | $4,793,047 |
| Buck Institute For Research On Aging | Biomedical research | 2023 | $650,000 |
| Morgan Stanley Global Impact Funding Trust Inc | Unrestricted general support | 2023 | $255,000 |
| Alzheimers Disease and Related Disorders Association Inc | Program support | 2023 | $247,500 |
| American Heart Association Inc | Research | 2023 | $144,580 |
| Oklahoma City Community Foundation Inc | General purpose | 2023 | $142,761 |
| American Lung Association | Research | 2023 | $100,000 |
| Broad Institute Inc | Research | 2023 | $68,240 |
Explore more
Data for Oklahoma Medical Research Foundation (EIN 73-0580274) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.